BMRN ▲ +0.2% - BioMarin Pharmaceutical Inc. $BMRN BMRN - BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence BioMarin Pharmaceutical rose 0.2% following the publication of positive Phase 3 results for VOXZOGO (vosoritide) in hypochondroplasia in NEJM Evidence. The data supports the potential regulatory and commercial viability of the therapy for this rare genetic bone disorder. 09-SEP-2026 09:07 AM ET